1,2-Dichloroethane → [(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl](2S)-1-[3-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoyl]piperidine-2-carboxylate

HRID 1754318ノート

反応式

HRID 1754318 の反応式
[F:1][C:2]1[CH:29]=[CH:28][CH:27]=[CH:26][C:3]=1[N:4]([CH2:16][C:17]1[CH:18]=[C:19]([CH:23]=[CH:24][CH:25]=1)[C:20](O)=[O:21])[C:5]([O:7][C@@H:8]1[CH:13]2[CH2:14][CH2:15][N:10]([CH2:11][CH2:12]2)[CH2:9]1)=[O:6].Cl.[Cl:31][C:32]1[CH:33]=[N+:34]([O-:60])[CH:35]=[C:36]([Cl:59])[C:37]=1[CH2:38][C@H:39]([O:50][C:51]([C@@H:53]1[CH2:58][CH2:57][CH2:56][CH2:55][NH:54]1)=[O:52])[C:40]1[CH:45]=[CH:44][C:43]([O:46][CH3:47])=[C:42]([O:48][CH3:49])[CH:41]=1.C(Cl)CCl>CN(C=O)C.CN(C1C=CN=CC=1)C>[Cl:31][C:32]1[CH:33]=[N+:34]([O-:60])[CH:35]=[C:36]([Cl:59])[C:37]=1[CH2:38][C@H:39]([O:50][C:51]([C@@H:53]1[CH2:58][CH2:57][CH2:56][CH2:55][N:54]1[C:20](=[O:21])[C:19]1[CH:23]=[CH:24][CH:25]=[C:17]([CH2:16][N:4]([C:5]([O:7][C@@H:8]2[CH:13]3[CH2:12][CH2:11][N:10]([CH2:15][CH2:14]3)[CH2:9]2)=[O:6])[C:3]2[CH:26]=[CH:27][CH:28]=[CH:29][C:2]=2[F:1])[CH:18]=1)=[O:52])[C:40]1[CH:45]=[CH:44][C:43]([O:46][CH3:47])=[C:42]([O:48][CH3:49])[CH:41]=1

参加物

6

反応物 3

HCID 111,2-DichloroethaneHCID 867202763-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoic acidHCID 86720277[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl](2S)-piperidine-2-carboxylate hydrochloride

生成物 1

HCID 76285017[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl](2S)-1-[3-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoyl]piperidine-2-carboxylate収率 42%

試薬・触媒・溶媒 2

HCID 142844-(Dimethylamino)pyridine触媒HCID 6228Dimethylformamide溶媒

実験手順

To a stirred solution of methyl 3-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate (4.12 g, 10 mmol) in tetrahydrofuran (45 mL) and methanol (45 mL) was added lithium hydroxide hydrate (839 mg, 20 mmol) in water (18 mL), and the mixture was stirred at room temperature for 24 hours. The solvent was removed in vacuo and the residue was purified using an SCX-2 cartridge eluting sequentially with methanol and 7 N methanolic ammonia. The product was triturated with THF (×5) and diethyl ether to give 3-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoic acid (3.51 g, 88%) as a white solid. To a solution of 3-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoic acid (76 mg, 0.19 mmol) in DMF (2 mL) was then added [(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl](2S)-piperidine-2-carboxylate hydrochloride (Int 6, 93 mg, 0.19 mmol), followed by DMAP (11 mg, 0.1 mmol) and EDC (72 mg, 0.37 mmol). The mixture was allowed to stir at room temperature for 5 hours, and then the solvent was removed in vacuo. The residue was partitioned between ethyl acetate (10 mL) and saturated sodium bicarbonate solution (10 mL). The separated organic phase was passed through a hydrophobic frit and the solvent was removed in vacuo. Purification was achieved by preparative HPLC to afford the title compound as a white solid (66 mg, 42%).

後処理

  1. customthe solvent was removed in vacuo
  2. customThe residue was partitioned between ethyl acetate (10 mL) and saturated sodium bicarbonate solution (10 mL)
  3. customthe solvent was removed in vacuo
  4. customPurification

出典と根拠

ORDレコード
ord-9ff3d15b6812486cb8e0969ed4781114
出典データセット
uspto-grants-2015_10
特許番号
US09169245B2

反応ノート

読み込み中…